Radiation-Induced Coronary Artery Disease During Immune Checkpoint Inhibitor Therapy: A Case Report

References

• Ravenholt RT . California chiropractors. An epidemiological study of causes of death among them and other characteristics. Calif. Med.101(5), 341–347 (1964).
   PubMedGoogle Scholar
• Donnellan E , PhelanD, McCarthyCP, CollierP, DesaiM, GriffinB. Radiation-induced heart disease: a practical guide to diagnosis and management. Cleve. Clin. J. Med.83(12), 914–922 (2016).
   PubMed Web of Science ®Google Scholar
• Fajardo LF , StewartJR. Experimental radiation-induced heart disease. I. Light microscopic studies. Am. J. Pathol.59(2), 299–316 (1970).
   PubMed Web of Science ®Google Scholar
• Pedersen LN , SchifferW, MitchellJD, BergomC. Radiation-induced cardiac dysfunction: practical implications. Kardiol. Pol. 80(3), 256–265 (2022).
   PubMed Web of Science ®Google Scholar
• Garg A , KumarP. Dosimetric comparison of the heart and left anterior descending artery in patients with left breast cancer treated with three-dimensional conformal and intensity-modulated radiotherapy. Cureus14(1), e21108 (2022).
   PubMedGoogle Scholar
• Pezner RD . Coronary artery disease and breast radiation therapy. Int. J. Radiat. Oncol. Biol. Phys.86(5), 816–818 (2013).
   PubMed Web of Science ®Google Scholar
• Darby SC , EwertzM, McgalePet al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med.368(11), 987–998 (2013).
   PubMed Web of Science ®Google Scholar
• Lancellotti P , NkomoVT, BadanoLPet al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J. Am. Soc. Echocardiogr.26(9), 1013–1032 (2013).
   PubMed Web of Science ®Google Scholar
• Atkins KM , BittermanDS, ChaunzwaTLet al. Mean heart dose is an inadequate surrogate for left anterior descending coronary artery dose and the risk of major adverse cardiac events in lung cancer radiation therapy. Int. J. Radiat. Oncol. Biol. Phys.110(5), 1473–1479 (2021).
   PubMed Web of Science ®Google Scholar
• Atkins KM , RawalB, ChaunzwaTLet al. Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer. J. Am. Coll. Cardiol.73(23), 2976–2987 (2019).
   PubMed Web of Science ®Google Scholar
• van Nimwegen FA , SchaapveldM, CutterDJet al. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J. Clin. Oncol.34(3), 235–43 (2016).
   PubMed Web of Science ®Google Scholar
• Van Nimwegen FA , SchaapveldM, JanusCPet al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern. Med.175(6), 1007–1017 (2015).
   PubMed Web of Science ®Google Scholar
• Al-Kindi SG , OliveiraGH. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clin. Proc.91(1), 81–83 (2016).
   PubMed Web of Science ®Google Scholar
• Atkins KM , ChaunzwaTL, LambaNet al. Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer. JAMA Oncol.7(2), 206–219 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang Z , LiuX, ChenD, YuJ. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct. Target. Ther.7(1), 258 (2022).
   PubMed Web of Science ®Google Scholar
• Du S , ZhouL, AlexanderGSet al. PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J. Thorac. Oncol.13(4), 510–520 (2018).
   PubMed Web of Science ®Google Scholar
• Yegya-Raman N , LeeSH, FriedesCet al. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation. Radiother. Oncol.190, 110005 (2024).
   PubMed Web of Science ®Google Scholar
• Lyon AR , López-FernándezT, CouchLSet al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J. Cardiovasc. Imaging23(10), e333–e465 (2022).
   PubMed Web of Science ®Google Scholar
• Saro H , Armenianet al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. JCO35, 893–911 (2017).
   PubMed Web of Science ®Google Scholar
• Lyon AR , YousafN, BattistiNML, MoslehiJ, LarkinJ. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol.19(9), e447–e458 (2018).
   PubMed Web of Science ®Google Scholar
• Chang HM , MoudgilR, ScarabelliT, OkwuosaTM, YehETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J. Am. Coll. Cardiol.70(20), 2536–2551 (2017).
   PubMedGoogle Scholar
• Virmani R , FarbA, CarterAJ, JonesRM. Comparative pathology: radiation-induced coronary artery disease in man and animals. Semin. Interv. Cardiol. 3(3–4), 163–172 (1998).
   PubMedGoogle Scholar
• Jaworski C , MarianiJA, WheelerG, KayeDM. Cardiac complications of thoracic irradiation. J. Am. Coll. Cardiol.61(23), 2319–2328 (2013).
   PubMed Web of Science ®Google Scholar
• Balanescu DV , DonisanT, DayahTet al. Refractory radiation-induced coronary artery disease: mapping the path and guiding treatment with optical coherence tomography. Int. J. Cardiovasc. Imaging35(5), 759–760 (2019).
   PubMed Web of Science ®Google Scholar
• Hussey P , WuI, JohnstonT. 2018 ACC/HRS/NASCI/SCAI/SCCT expert consensus document on optimal use of ionizing radiation in cardiovascular imaging: best practices for safety and effectiveness – a review for the cardiac anesthesiologist. J. Cardiothorac. Vasc. Anesth.33(11), 2902–2908 (2019).
   PubMed Web of Science ®Google Scholar
• Venkatesulu BP , MahadevanLS, AliruMLet al. Radiation-induced endothelial vascular injury: a review of possible mechanisms. JACC Basic Transl. Sci.3(4), 563–572 (2018).
   PubMedGoogle Scholar
• Cuomo JR , JavaheriSP, SharmaGK, KapoorD, BermanAE, WeintraubNL. How to prevent and manage radiation-induced coronary artery disease. Heart104(20), 1647–1653 (2018).
   PubMed Web of Science ®Google Scholar
• Orzan F , BruscaA, ConteMR, PresbiteroP, FigliomeniMC. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br. Heart J.69(6), 496–500 (1993).
   PubMedGoogle Scholar
• Om A , VetrovecGW. Coronary angioplasty of radiation-induced stenosis. Am. Heart J.125(4), 1164–1166 (1993).
   PubMed Web of Science ®Google Scholar
• McEniery PT , DorostiK, SchiavoneWA, PedrickTJ, SheldonWC. Clinical and angiographic features of coronary artery disease after chest irradiation. Am. J. Cardiol.60(13), 1020–1024 (1987).
   PubMed Web of Science ®Google Scholar
• Ruiz CR , Mesa-PabónM, SotoK, RománJH, López-CandalesA. Radiation-induced coronary artery disease in young patients. Heart Views19(1), 23–26 (2018).
   PubMedGoogle Scholar
• Levine GN , BatesER, BlankenshipJCet al. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc. Interv.79(3), 453–495 (2012).
   PubMed Web of Science ®Google Scholar
• Gaya AM , AshfordRF. Cardiac complications of radiation therapy. Clin. Oncol. (R. Coll. Radiol.)17(3), 153–159 (2005).
   PubMed Web of Science ®Google Scholar
• Dezorzi C . Radiation-induced coronary artery disease and its treatment: a quick review of current evidence. Cardiol. Res. Pract.2018, 8367268 (2018).
   PubMed Web of Science ®Google Scholar
• Darby SC , CutterDJ, BoermaMet al. Radiation-related heart disease: current knowledge and future prospects. Int. J. Radiat. Oncol. Biol. Phys.76(3), 656–665 (2010).
   PubMed Web of Science ®Google Scholar
• Bradley JD , HuC, KomakiRRet al. Long-term results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J. Clin. Oncol.38(7), 706 (2020).
   PubMed Web of Science ®Google Scholar
• Lee SH , GengH, ArnoldJet al. Interpretable Machine Learning for Choosing Radiation Dose-volume Constraints on Cardio-pulmonary Substructures Associated with Overall Survival in NRG Oncology RTOG 0617. Int. J. Radiat. Oncol. Biol. Phys.117(5), 1270–1286 (2023).
   PubMed Web of Science ®Google Scholar
• Demirci S , NamJ, HubbsJL, NguyenT, MarksLB. Radiation-induced cardiac toxicity after therapy for breast cancer: interaction between treatment era and follow-up duration. Int. J. Radiat. Oncol. Biol. Phys.73(4), 980–987 (2009).
   PubMed Web of Science ®Google Scholar
• Rehammar JC , JensenMB, McGalePet al. Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977–2005. Radiother. Oncol.123(2), 299–305 (2017).
   PubMed Web of Science ®Google Scholar
• Yeboa DN , EvansSB. Contemporary breast radiotherapy and cardiac toxicity. Semin. Radiat. Oncol.26(1), 71–78 (2016).
   PubMed Web of Science ®Google Scholar
• Marks LB , YorkeED, JacksonAet al. Use of normal tissue complication probability models in the clinic. Int. J. Radiat. Oncol. Biol. Phys.76(Suppl. 3), S10–S19 (2010).
   PubMed Web of Science ®Google Scholar
• Brown KN , HussainK, RichardsJR. Radiation induced coronary artery disease. In: StatPearls.StatPearls Publishing, FL, USA (2022).
   Google Scholar
• Task Force Members , MontalescotG, SechtemUet al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J.34(38), 2949–3003 (2013).
   PubMed Web of Science ®Google Scholar
• Visseren FLJ , MachF, SmuldersYMet al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J.42(34), 3227–3337 (2021).
   PubMed Web of Science ®Google Scholar
• Wei J , XuH, LiuY, LiB, ZhouF. Effect of captopril on radiation-induced TGF-β1 secretion in EA.Hy926 human umbilical vein endothelial cells. Oncotarget8(13), 20842–20850 (2017).
   PubMedGoogle Scholar
• Wilkinson EL , SidawayJE, CrossMJ. Statin regulated ERK5 stimulates tight junction formation and reduces permeability in human cardiac endothelial cells. J. Cell. Physiol.233(1), 186–200 (2018).
   PubMed Web of Science ®Google Scholar
• O’Herron T , LaffertyJ. Prophylactic use of colchicine in preventing radiation induced coronary artery disease. Med. Hypotheses111, 58–60 (2018).
   PubMed Web of Science ®Google Scholar
• Annest LS , AndersonRP, LiW, HafermannMD. Coronary artery disease following mediastinal radiation therapy. J. Thorac. Cardiovasc. Surg.85(2), 257–263 (1983).
   PubMed Web of Science ®Google Scholar
• Veeragandham RS , GoldinMD. Surgical management of radiation-induced heart disease. Ann. Thorac. Surg.65(4), 1014–1019 (1998).
   PubMed Web of Science ®Google Scholar
• Schömig K , NdrepepaG, MehilliJ, PacheJ, KastratiA, SchömigA. Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. Catheter Cardiovasc. Interv. 70(3), 359–365 (2007).
   PubMed Web of Science ®Google Scholar
• Caio G . Myocarditis with immune checkpoint blockade. N. Engl. J. Med.376(3), 291–292 (2017).
   PubMedGoogle Scholar
• Johnson DB , BalkoJM, ComptonMLet al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med.375(18), 1749–1755 (2016).
   PubMed Web of Science ®Google Scholar
• Grabie N , LichtmanAH, PaderaR. T cell checkpoint regulators in the heart. Cardiovasc. Res.115(5), 869–877 (2019).
   PubMed Web of Science ®Google Scholar
• Wang WX , SongZZ, ZhangYP. Cardiovascular toxicities associated with immune checkpoint inhibitors. Zhonghua Zhong Liu Za Zhi42(7), 609–613 (2020).
   PubMedGoogle Scholar
• Grabie N , GotsmanI, DacostaRet al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation116(18), 2062–2071 (2007).
   PubMed Web of Science ®Google Scholar
• Libby P , RidkerPM, HanssonGK. Progress and challenges in translating the biology of atherosclerosis. Nature473(7347), 317–325 (2011).
   PubMed Web of Science ®Google Scholar
• Zhao TX , MallatZ. Targeting the immune system in atherosclerosis: JACC state-of-the-art review. J. Am. Coll. Cardiol.73(13), 1691–1706 (2019).
   PubMed Web of Science ®Google Scholar
• Bu DX , TarrioM, Maganto-GarciaEet al. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler. Thromb. Vasc. Biol.31(5), 1100–1107 (2011).
   PubMed Web of Science ®Google Scholar
• Foks AC , KuiperJ. Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. Br. J. Pharmacol.174(22), 3940–3955 (2017).
   PubMed Web of Science ®Google Scholar
• Gelsomino F , FiorentinoM, ZompatoriMet al. Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques? Ann. Oncol. 29(1), 284–286 (2018).
   PubMed Web of Science ®Google Scholar
• Cautela J , RoubyF, SalemJEet al. Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event. Can. J. Cardiol.36(4), 476–481 (2020).
   PubMed Web of Science ®Google Scholar
• Son C , MoeyMYY, WalkerPR, NaqashAR, PeachMS, JuAW. Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy. Front. Oncol.12, 1025455 (2022).
   PubMed Web of Science ®Google Scholar
• Calabretta R , HoellerC, PichlerVet al. Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries. Circulation142(24), 2396–2398 (2020).
   PubMed Web of Science ®Google Scholar
• Newman JL , StoneJR. Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis. Cardiovasc. Pathol. 43, 107148 (2019).
   PubMed Web of Science ®Google Scholar
• Drobni ZD , AlviRM, TaronJet al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation142(24), 2299–2311 (2020).
   PubMed Web of Science ®Google Scholar
• Cheng Y , NieL, MaW, ZhengB. Early onset acute coronary artery occlusion after pembrolizumab in advanced non-small cell lung cancer: a case report. Cardiovasc. Toxicol. 21(8), 683–686 (2021).
   PubMed Web of Science ®Google Scholar
• Antonia SJ , VillegasA, DanielDet al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med.377(20), 1919–1929 (2017).
   PubMed Web of Science ®Google Scholar
• Jabbour SK , LeeKH, FrostNet al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol.7(9), 1–9 (2021).
   PubMed Web of Science ®Google Scholar